Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of SAR441566 in moderate-to-severe ulcerative colitis
jRCT2031250090Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of balinatunfib in autoimmune colitis (4 arms), sponsored by Sanofi. Primary endpoint: Clinical remission by modified Mayo Score at Week 12. Started Aug 2025; status: active, not recruiting.
02
Drugs
balinatunfib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031250090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250090.